Most pharmaceutical companies want their name on the label. Dr. Murali K. Divi built a billion-dollar company by staying behind it. Divi’s Laboratories does not sell a single tablet to a patient. Instead, it manufactures the active pharmaceutical ingredients and custom synthesis intermediates that go inside the tablets sold by six of the world’s ten largest pharmaceutical companies. From two sprawling campuses in Andhra Pradesh, one of them inside a dedicated special economic zone, Divi’s has quietly become one of the top three API producers on the planet — with 60–85% global market share in select molecules like naproxen, gabapentin, and dextromethorphan (per investor presentations).
Walk into any pharmacy in the world and pick up a bottle of naproxen for a headache, a prescription for gabapentin for nerve pain, or a cough syrup containing dextromethorphan. There is a meaningful chance that the active ingredient inside that medicine was manufactured in a facility on the outskirts of Visakhapatnam, India, by a company most consumers have never heard of. That is by design. Divi’s Laboratories operates in the deepest layer of the pharmaceutical supply chain, making the chemical compounds that other companies turn into branded and generic medicines.
The business model is built on two pillars. The first is generic APIs — active pharmaceutical ingredients sold to formulators around the world, where Divi’s competes on purity, cost, and reliability of supply. The company manufactures roughly thirty commercial molecules, but it does not spread thin across hundreds. Instead, it picks molecules where chemistry and scale create a durable advantage, then manufactures them in volumes large enough to dominate global market share. Naproxen alone accounts for an estimated 60–85% of the world’s supply from Divi’s plants.
The second pillar is custom synthesis — contract manufacturing for global innovator pharmaceutical companies that outsource complex intermediate and API production to trusted partners. By FY 2025, custom synthesis contributed approximately 56% of quarterly revenue, a shift from the historically API-heavy mix that reflects growing trust from multinational clients. Six of the world’s top ten pharmaceutical companies are Divi’s customers, and the relationships are measured in decades, not purchase orders.
What separates Divi’s from hundreds of other API manufacturers is backward integration and process chemistry. Dr. Murali Divi, a U.S.-trained organic chemist, built the company around a principle borrowed from his academic training: if you understand a reaction deeply enough, you can find a way to run it cheaper, cleaner, and at larger volumes than anyone else. The company develops its manufacturing processes in-house, starting from the earliest intermediates and integrating backward to the point where it controls both cost and quality at every step.
This approach demands enormous capital investment in reactors, distillation columns, and solvent-recovery systems. But it produces two structural advantages. First, backward integration compresses margins that would otherwise leak to intermediate suppliers — Divi’s EBITDA margins have historically hovered around 30–40%, among the highest in the Indian API industry. Second, it creates a process-knowledge moat: even if a competitor knows which molecule to make, replicating the specific process route that Divi’s has optimized over decades is extraordinarily difficult.
The company also moved early into nutraceutical ingredients, producing carotenoids like beta-carotene, lutein, and lycopene. This segment, which accounts for roughly 10–15% of revenue, leverages the same fermentation and extraction capabilities used in pharmaceutical APIs but serves the food and nutrition industry — a diversification that smooths demand cycles.
In 2006, Divi’s made a decision that would define its next two decades: it developed its own special economic zone near Visakhapatnam, Andhra Pradesh. The Divi’s Pharma SEZ houses dedicated manufacturing units that benefit from export-oriented tax incentives and streamlined regulatory clearances. When the company needed to expand further, it chose Kakinada, also in Andhra Pradesh, acquiring 500 acres for a third manufacturing complex that began commercial operations in its first phase during FY 2024.
The geographic concentration is deliberate. Rather than scattering plants across multiple states, Divi’s keeps its manufacturing within Andhra Pradesh and Telangana, where it can share infrastructure, rotate technical staff, and maintain a single quality culture across all facilities. Today the company operates six manufacturing units: two in Choutuppal (Telangana, near Hyderabad) and four in the Visakhapatnam area, plus the Kakinada expansion. All major facilities carry US FDA and EU regulatory registrations.
Roughly 88–90% of Divi’s revenue comes from exports, with North America and Europe together contributing about 74% of sales. The domestic market accounts for only 10–12% of revenue — a lopsided ratio that reflects the company’s role as a supplier to the world’s largest generic formulators and innovator pharmaceutical firms, not to Indian pharmacies.
Divi’s exports to more than 100 countries, but the revenue concentration tells the real story: North America and Europe dominate. The company supplies APIs and intermediates to twelve of the world’s twenty largest pharmaceutical companies, and its custom synthesis relationships are anchored by multi-year agreements with innovator firms headquartered in the United States, Switzerland, and Germany. The business segment mix has shifted meaningfully toward custom synthesis, which overtook generic APIs in quarterly revenue contribution by late FY 2025.
Divi’s operates six multi-purpose manufacturing facilities spread across Telangana and Andhra Pradesh, with a combined installed capacity that ranks among the largest dedicated API manufacturing footprints in the world. The Visakhapatnam complex alone, including the SEZ and export-oriented units, spans hundreds of acres. The newer Kakinada facility, built on a 500-acre site with an initial investment of ₹1,200–1,500 crore, is designed for both generic APIs and custom synthesis, and its phased expansion will add significant capacity through the remainder of the decade.
The regulatory portfolio mirrors the export-heavy business model: all major manufacturing units carry US FDA registration, and the company holds Drug Master Files across the United States, Europe, Japan, and dozens of other regulated markets. Divi’s has weathered FDA scrutiny — including warning letters in 2017 that temporarily constrained new product approvals — and emerged with remediated facilities and restored compliance status. The company holds 35 Indian Patent Office grants, weighted toward process innovations and intermediate chemistry.
Sources: Divi’s Laboratories Annual Reports FY2019–20 through FY2024–25. Divi’s Laboratories Q2 FY2026 Earnings Call Transcript. US FDA facility registration and inspection records. Indian patent office records. Company investor presentations.